Roberto Castelli Selected Research

Acquired angioedema

8/2018	Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.
9/2013	Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship.
2/2013	Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic.
12/2008	Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto Castelli Research Topics

Disease

10	Neoplasms (Cancer) 01/2020 - 05/2004
8	Multiple Myeloma 05/2022 - 07/2010
8	Lymphoma (Lymphomas) 01/2020 - 07/2010
7	Thrombosis (Thrombus) 05/2022 - 07/2010
5	Hemorrhage 05/2022 - 05/2004
5	Angioedema 08/2018 - 12/2008
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2017 - 05/2007
4	Infections 04/2020 - 12/2014
4	Anemia 01/2019 - 09/2014
4	Acquired angioedema 08/2018 - 12/2008
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2018 - 02/2013
4	Paraproteinemias (Monoclonal Gammopathy) 12/2014 - 05/2007
3	Venous Thromboembolism 05/2022 - 05/2004
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 02/2013
2	COVID-19 05/2022 - 04/2020
2	Chronic Renal Insufficiency 01/2019 - 01/2019
2	Iron Deficiencies 01/2019 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 01/2018
2	Essential Thrombocythemia 01/2019 - 01/2018
2	Rare Diseases (Rare Disease) 08/2018 - 09/2013
2	Thrombocytosis (Thrombocythemia) 01/2018 - 04/2015
2	Hereditary Angioedemas 02/2013 - 05/2007
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 08/2012 - 01/2002
1	Delirium 05/2022
1	Respiratory Insufficiency (Respiratory Failure) 05/2022
1	Sepsis (Septicemia) 05/2022
1	Non-alcoholic Fatty Liver Disease 10/2021
1	Weight Loss (Weight Reduction) 10/2021
1	Disseminated Intravascular Coagulation 01/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Eosinophilia 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021
1	Thromboembolism 04/2020
1	Disease Progression 01/2020
1	Thrombotic Microangiopathies 01/2020
1	AIDS-Related Lymphoma (Lymphoma, AIDS Related) 01/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2017
1	Hepatitis B 11/2016
1	Hepatitis 11/2016
1	Cytopenia 01/2016

Drug/Important Bio-Agent (IBA)

4	Rituximab (Mabthera)FDA Link 01/2021 - 01/2016
4	Epoetin Alfa (Epogen)FDA Link 01/2019 - 09/2014
4	Biosimilar PharmaceuticalsIBA 01/2019 - 09/2014
4	Complement System Proteins (Complement)IBA 08/2018 - 12/2008
4	AutoantibodiesIBA 12/2014 - 05/2007
3	CytokinesIBA 05/2022 - 07/2010
3	C-Reactive ProteinIBA 10/2021 - 06/2012
3	Bendamustine Hydrochloride FDA Link 01/2021 - 01/2016
3	HematinicsIBA 01/2019 - 04/2018
3	Heparin (Liquaemin)FDA LinkGeneric 01/2019 - 05/2004
3	Immunomodulating AgentsIBA 12/2014 - 10/2012
3	Peptides (Polypeptides)IBA 09/2013 - 12/2008
3	BradykininIBA 09/2013 - 12/2008
2	Thrombin FDA Link 10/2021 - 10/2011
2	von Willebrand FactorIBA 10/2021 - 06/2012
2	Factor VII (Proconvertin)IBA 10/2021 - 06/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 10/2021 - 06/2012
2	Fibrinogen (Factor I)FDA Link 10/2021 - 06/2012
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 07/2010
2	Hemostatics (Antihemorrhagics)IBA 04/2020 - 12/2014
2	Hemoglobins (Hemoglobin)IBA 01/2019 - 01/2019
2	IronIBA 01/2019 - 01/2019
2	EndotoxinsIBA 12/2014 - 07/2010
2	Factor XII (Hageman Factor)IBA 12/2014 - 07/2010
2	GlycosaminoglycansIBA 12/2014 - 07/2010
2	Thromboplastin (Tissue Factor)IBA 12/2014 - 07/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2014 - 07/2010
2	AntibodiesIBA 09/2013 - 02/2010
1	Protein SIBA 10/2021
1	Plasminogen Activator Inhibitor 1IBA 10/2021
1	AntigensIBA 10/2021
1	LipidsIBA 10/2021
1	HomocysteineIBA 10/2021
1	Retinoic Acid Receptor alphaIBA 10/2021
1	bosutinibIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	ArsenicIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	eltrombopag FDA Link 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Prednisone (Sone)FDA LinkGeneric 01/2021
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2021
1	mepolizumabIBA 01/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Thrombopoietin ReceptorsIBA 11/2020
1	ADAMTS13 ProteinIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	ibrutinibIBA 11/2019

Therapy/Procedure

9	Therapeutics 01/2021 - 05/2004
8	Drug Therapy (Chemotherapy) 01/2020 - 07/2010
1	Palliative Care (Palliative Therapy) 05/2022
1	Punctures 05/2022
1	Catheters 05/2022
1	Continuous Positive Airway Pressure 05/2022
1	Platelet Transfusion (Blood Platelet Transfusions) 01/2021
1	Highly Active Antiretroviral Therapy (HAART) 01/2020
1	Polypharmacy 02/2018
1	Radiotherapy 01/2016